August 10, 2020
Nordic Nanovector Appoints Dr Christine Wilkinson Blanc as Chief Medical Officer
Media
August 07, 2020
Oncopeptides initiates the first study with melflufen outside multiple myeloma and enrolls the first patient in the phase 1/2 AL amyloidosis study
August 06, 2020
Independent Review Committee Recommends Nordic Nanovector to focus on one dosage arm for the Pivotal PARADIGME Phase 2b Trial in Patients with 3L R/R FL
August 05, 2020
Fusion Pharmaceuticals To Present At The 2020 Wedbush PacGrow Healthcare Virtual Conference
August 05, 2020
Q2 2020 General Market Overview
August 04, 2020
Oncopeptides starts the phase 2 PORT study comparing peripheral versus central administration of melflufen and dexamethasone in multiple myeloma
August 04, 2020
Strongbridge Biopharma plc Reports Second Quarter 2020 Financial Results and Provides Corporate Update
August 04, 2020
GenSight Biologics draws down the €4 million second tranche of bonds from Kreos Capital
July 30, 2020
Nordic Nanovector Announces EU Patent Granted Covering the Use of Alpha37
July 30, 2020
GenSight Biologics Reports Interim Financial Results for the First Half of 2020 and Provides Operational Update
